NetraMark appoints Dr. Panteli Theocharous as Fractional Chief Medical Officer to boost global AI-driven clinical trials.

NetraMark Holdings Inc. has appointed Dr. Panteli Theocharous as its Fractional Chief Medical Officer to enhance clinical leadership and accelerate the global adoption of its AI platform, NetraAI. Dr. Theocharous brings extensive expertise in clinical development and strategy, aiming to improve trial design and patient stratification using explainable AI. This move supports NetraMark's goal to increase trial success rates and efficiency by integrating advanced AI with clinical insights. The company also acknowledged outgoing CMO Dr. Larry Alphs, who will remain as an advisor during this transition.